Navigation Links
Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
Date:10/12/2007

ANALYST AVAILABLE TO COMMENT ON THE MARKET FORECAST FOR THE DRUG

WALTHAM, Mass., Oct. 12 /PRNewswire/ -- Dr. Sylvia Eash, Ph.D., analyst at Decision Resources, is available to discuss the impact of the Food and Drug Administration's (FDA) possible approval of Merck's Isentress, the first integrase inhibitor drug which blocks the ability of the HIV virus to replicate and infect new cells.

Integrase inhibitors are a novel class of HIV drugs aimed at a previously unexploited viral target. They are a key new class that will expand therapeutic options for HIV patients and stand out as one of the most promising emerging classes in development for HIV. The reported efficacy and safety data from clinical trials of Isentress indicate that the product is highly efficacious, safe, well tolerated in both treatment-naive and treatment-experienced HIV patients. The clinical data on Isentress presented to date suggests that there is significant opportunity for follow-on agents in this new class of HIV drugs.

Isentress is expected to launch during the fourth quarter of 2007, according to Merck.

Dr. Eash can provide:

-- Insight on the class of integrase inhibitors and particularly Isentress

and its potential effect on other drugs in the HIV market.

-- Key factors that will have an impact on Isentress's uptake and use. How

will Isentress be positioned in the lines of HIV treatment?

-- The main drivers and barriers for its use. What is the forecast for

Isentress? Which drugs will be its main competition?

-- Key thought leaders' perceptions about Isentress.

-- Isentress's impact on the HIV market and on the overall HIV therapeutic

approach.

Sylvia Eash, Ph.D., is an analyst with Decision Resources Infectious Disease group, where she evaluates emerging therapies and develops market forecasts. She has a doctoral degree in pathobiology from Brown University. Dr. Eash is the author of several peer-reviewed primary literature and review articles, and she is a member of the American Society for Microbiology and the International Society of Neurovirology.

To talk with Dr. Eash, please contact Erica Ames at 781-296-2583 or eames@dresources.com.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Erica Ames

781-296-2583

eames@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. A Vaccine for the impending pandemic Avian Influenza
2. India warned of Impending AIDS Disaster
3. 3-D Ultrasound Identifies Women at Risk for Impending Preterm Birth
4. Now, Cellphones That Alert Against Impending Lightning Strikes
5. WHO Gives Its Approval For Bird Flu Test Kit
6. Ranbaxy gets US FDA approval for Lisinopril
7. Approval for DNA test to detect cystic fibrosis
8. Aurobindo gets U.S. FDA approval for Cephalexin
9. Cadila gets US FDA approval for Promethazine tablets
10. Vaccine For Cervical Cancer Awaits Approval
11. Anti-obesity drugs for FDA approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations ... literacy software tool, and the Cancer Patient Education Network (CPEN), an independent professional ... announce a new strategic alliance. , As CPEN’s strategic partner, HLI will ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)... 2, 2017 Halo Labs announces the European launch of ... the HORIZON at MIBio 2017 in Cambridge, U.K ... particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity while ... technique Backgrounded Membrane Imaging. ... HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
Breaking Medicine Technology: